Perimenopause and Bone Health: The Critical Window You Cannot Miss

Bone density loss accelerates most rapidly during the perimenopause transition — but most women are not told this until it is already advanced. Here is what to do during the window when action has the greatest impact.

Osteoporosis is often described as a disease that affects older women — a postmenopausal concern for women in their 60s and 70s. This framing is both clinically inaccurate and practically harmful, because it locates the problem at a point in life when the most effective preventive interventions have already passed their window of maximum impact. The reality is that the accelerated bone density loss that eventually leads to osteoporosis begins during perimenopause — and the perimenopause years are when protective action has its greatest effect.

Understanding this is important not because bone health is more important than symptom management, but because it is a genuinely significant long-term health implication of the perimenopause transition that is consistently under-communicated to women who are in the exact window when they could do the most about it.

What Oestrogen Does for Bones — and What Happens When It Declines

Bone is not static tissue. It is continuously remodelled — old bone broken down by cells called osteoclasts, new bone built by cells called osteoblasts — in a carefully regulated process that maintains bone density and structural integrity throughout life. Oestrogen plays a critical role in this process: it inhibits osteoclast activity, meaning that adequate oestrogen prevents excessive bone breakdown. When oestrogen is present at adequate levels, the balance between bone breakdown and bone formation is maintained. When oestrogen declines, osteoclast activity accelerates unchecked, and bone is broken down faster than it is rebuilt.

Bone density loss begins to accelerate several years before the final menstrual period — during the hormonal fluctuations of perimenopause — and reaches its fastest rate in the two to three years immediately around the final period. The cumulative bone density loss during perimenopause and the immediate postmenopausal years can be substantial. This is the window that matters most for intervention.

The long-term consequence of inadequate bone density is fracture risk — particularly hip, wrist, and vertebral fractures, which are associated with significant morbidity and, in the case of hip fractures in older women, with substantial mortality. One in two women over 50 will experience an osteoporosis-related fracture in their lifetime. Preventing or substantially reducing that risk requires action during perimenopause, not after it.

Assessing Your Starting Point

The first practical step in perimenopause bone health management is understanding your current risk level and baseline bone density. Several factors significantly increase the risk of osteoporosis and therefore increase the urgency of protective action during perimenopause.

Family history of osteoporosis or low-trauma fracture in a first-degree relative (parent or sibling) is one of the strongest risk factors for osteoporosis — partly through genetic predisposition and partly because many risk factors are familial. Low body weight or a history of being underweight increases risk, because bone density is partly maintained by the mechanical loading of body weight on the skeleton. A history of smoking, significant alcohol consumption, and prolonged glucocorticoid (steroid) use all increase osteoporosis risk. Early menopause — before age 45 — significantly increases osteoporosis risk because of the earlier and longer duration of oestrogen deficiency.

DEXA scanning — dual-energy X-ray absorptiometry — is the standard clinical tool for measuring bone mineral density. It is not routinely offered to all perimenopausal women on the NHS, but it is a reasonable request and is likely to be agreed if you have one or more significant risk factors. DEXA scanning gives you a T-score that places your bone density in context: a score of zero is the average for a healthy young adult, negative one to negative two point five indicates osteopenia (reduced bone density), and below negative two point five indicates osteoporosis. Knowing your T-score gives you a quantitative baseline against which the effect of protective interventions can be measured over time.

Exercise — The Primary Bone-Protective Intervention

Weight-bearing exercise is the most evidence-supported non-pharmacological intervention for bone protection during perimenopause. The mechanism is mechanical: bones respond to the loads placed on them by building additional density in the areas under load. Weight-bearing exercises — those where your skeleton carries your body weight against gravity — produce this stimulating load; non-weight-bearing exercises like swimming and cycling, while excellent for cardiovascular health, do not produce the same bone-forming stimulus.

Walking is weight-bearing and accessible, and regular brisk walking has documented benefits for bone density. Running and hiking place greater load on bones than walking and produce greater bone-stimulating effects. Strength training — lifting weights, resistance machines, body-weight exercises — is particularly effective because it places load on bones through both the weight being lifted and the muscle contraction forces that accompany the movement. Strong muscles create stronger bones; the relationship is direct and bidirectional.

Impact exercise — activities involving jumping, hopping, or high-impact landing — places very high momentary loads on bones and has a strong evidence base for bone stimulation. Trampolining, jumping rope, dance, and high-impact aerobics all count. These activities are not appropriate for women who already have low bone density and elevated fracture risk, where the impact itself could cause fracture — but for women with normal or mildly reduced bone density, impact exercise is one of the most effective bone-building activities available.

Calcium and Vitamin D — The Nutritional Foundation

Calcium is the primary mineral component of bone — approximately 99% of the body's calcium is stored in the skeleton. Adequate dietary calcium is essential for maintaining bone density, and calcium requirements do not decrease with age — they remain significant throughout the postmenopausal years. UK guidance recommends 700mg of calcium per day, though many bone health experts suggest that perimenopausal and postmenopausal women benefit from 1000 to 1200mg daily.

Good food sources of calcium include dairy products (milk, yoghurt, cheese), fortified plant milks, tinned sardines and salmon with bones, leafy green vegetables (particularly kale, bok choy, and broccoli), almonds, and fortified cereals. For most women, adequate calcium can be achieved through diet without supplementation, but this requires conscious attention to calcium-containing foods rather than assuming calcium needs are met passively.

Vitamin D is essential for calcium absorption from the gut — without adequate vitamin D, dietary calcium cannot be absorbed effectively regardless of intake. Vitamin D is produced primarily through sun exposure to the skin, and UK Public Health England recommends that everyone consider vitamin D supplementation of 400IU (10 micrograms) daily during autumn and winter, when sun exposure is insufficient. Women with darker skin tones, limited outdoor exposure, or other risk factors for vitamin D deficiency may need higher supplementation year-round. For bone health specifically, vitamin D levels of 400 to 800IU daily are typically recommended, though optimal dosing should be discussed with your GP, particularly if you have risk factors for deficiency.

HRT — The Hormonal Intervention

HRT started during perimenopause has well-documented bone-protective effects. By restoring oestrogen levels, HRT directly restores the inhibition of osteoclast activity that oestrogen provides — essentially pausing or reversing the accelerated bone density loss that oestrogen decline drives. Studies consistently show that women who take HRT during perimenopause and early postmenopause have significantly higher bone density than those who do not.

The bone protection provided by HRT is one of the significant long-term health benefits that is frequently omitted from discussions of HRT risks and benefits. When the breast cancer risk is presented (accurately, and in context) but the bone protection benefit is not mentioned, women are receiving an incomplete picture of the risk-benefit profile — one that may influence them toward a decision that is not in their long-term interest.

Cardiovascular Health — The Connected Picture

Bone health and cardiovascular health are connected through the same oestrogen-decline mechanism, and they deserve to be considered together. Oestrogen protects the cardiovascular system through several mechanisms: it supports healthy cholesterol ratios, promotes arterial flexibility, and has anti-inflammatory effects on blood vessel walls. As oestrogen declines during perimenopause, cardiovascular risk increases — and perimenopause is the window when preventive lifestyle and pharmacological interventions have their greatest effect on long-term cardiovascular outcomes.

The lifestyle interventions that protect bone — regular exercise, adequate nutrition, not smoking, moderating alcohol — also protect the cardiovascular system. HRT started during perimenopause is associated with reduced cardiovascular risk in women who begin it within ten years of menopause. And blood pressure, cholesterol, and cardiovascular risk assessment are as important a part of perimenopause health management as symptom treatment.